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Abstract Purpose: Anti-virulence
strategies have not been evaluated for
the prevention of bacterial infections.
Prolonged colonization of intubated
patients with Pseudomonas aerugin-
osa isolates producing high-levels of
the quorum sensing (QS)-regulated
virulence factor rhamnolipids has
been associated with ventilator-asso-
ciated pneumonia (VAP). In this
pathogen, azithromycin reduces QS-
regulated virulence. We aimed to
assess whether azithromycin could
prevent VAP in patients colonized by
rhamnolipids producing isolates.
Methods: In a randomized, double-
blind, multicenter trial, intubated
colonized patients received either
300 mg/day azithromycin or placebo.
Primary endpoint was the occurrence
of P. aeruginosa VAP. We further
identified those patients persistently
colonized by isolates producing high-
levels of rhamnolipids and therefore
at the highest risk to develop VAP
linked to this QS-dependent virulence
factor. Results: Ninety-two patients
were enrolled; 43 azithromycin-trea-
ted and 42 placebo patients were
eligible for the per-protocol analysis.
In the per-protocol population, the
occurrence of P. aeruginosa VAP
was reduced in the azithromycin
group but without reaching statistical
significance (4.7 vs. 14.3 % VAP,
p = 0.156). QS-dependent virulence
of colonizing isolates was similarly
low in both study groups, and only
five patients in each arm were per-
sistently colonized by high-level
rhamnolipids producing isolates. In
this high-risk subgroup, the incidence
of VAP was reduced fivefold in
azithromycin versus placebo patients
(1/5 vs. 5/5 VAP, p = 0.048). Con-
clusions: There was a trend towards
reduced incidence of VAP in colo-
nized azithromycin-treated patients.
In addition, azithromycin signifi-
cantly prevented VAP in those
patients at high risk of rhamnolipid-
dependent VAP, suggesting that vir-
ulence inhibition is a promising anti-
microbial strategy.
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Introduction
Multi-drug-resistant bacteria represent a major medical
threat, contributing to the deaths of increasing numbers of
patients worldwide. To face this serious challenge, alter-
native strategies aiming at the inhibition of bacterial
virulence have been proposed [1]. Due to the absence of
selective pressure, such strategies are believed to mini-
mize the risk of emergence of resistant clones [2, 3]. To
our knowledge, however, no clinical study has demon-
strated the feasibility of such an approach.
Pseudomonas aeruginosa is a leading cause of venti-
lator-associated pneumonia (VAP) [4–6]. This pathogen
frequently develops resistance to available antimicrobial
agents [7–9]. Improved treatments and/or preventive
measures are urgently required since attributable mortal-
ity of this condition remains high [6]. Whereas almost all
cases of P. aeruginosa-associated VAP are preceded by
colonization of the respiratory tract, only 10–20 % of
colonized patients eventually evolve to VAP [4]. Quorum
sensing (QS) is a complex signaling network that allows
coordinated gene expression according to cell density [1]
and regulates many major virulence factors in P. aeru-
ginosa [10]. As a consequence, QS is an ideal target for
anti-virulence strategies. Macrolides, like azithromycin,
are neither bactericidal nor bacteriostatic for P. aerugin-
osa at clinically achievable concentrations and are
therefore unlikely to select resistant clones. However, at
these concentrations, azithromycin inhibits QS in vitro
[11–14]. Furthermore, we have shown that azithromycin
reduces the expression of QS-circuit and target genes in
patient [15]. Azithromycin has a favorable profile in
terms of pharmacokinetics and of metabolism. Lung tis-
sue distribution is high, enabling to reach QS-inhibitory
concentrations (2–4 lg/ml) in bronchial mucosa, epithe-
lial lining fluid, and sputum after a single 500-mg dose
[16]. No clinical trial has previously investigated a viru-
lence inhibition strategy for the prevention of bacterial
infections. Thus, we decided to conduct a proof-of-con-
cept study, designed as a multicenter, randomized,
double-blind, placebo-controlled trial to evaluate azith-
romycin for the prevention of P. aeruginosa VAP in
colonized mechanically ventilated patients.
Methods
Study population
This pilot, randomized, placebo-controlled, double-blind
study (ANB 006#2001, ClinicalTrials.gov ID#NCT00
610623) was designed to assess the efficacy of azithromycin
as a quorum-sensing inhibitor in preventing the occurrence
of P. aeruginosa pneumonia in ventilated patients with
documented colonization in bronchial aspirates at study
entry. We obtained approval for this multicenter European
study by the respective local ethics committees and national
agencies. Written consent from all patients or their legal
representatives was obtained according to legal and ethical
considerations. The study took place between November
2002 and November 2005. Twenty-one European centers
participated in this trial; eight in France, four in Spain, two in
Belgium, three in Poland, two in Serbia, and two in Swit-
zerland. We screened mechanically ventilated patients for
respiratory tract colonization by P. aeruginosa on alternate
days. Eligible patients were adults between 18 and 75 years
of age, hospitalized in the ICU under mechanical ventilation
expected to be required for at least 3 days, with a reasonable
surviving chance (Apache score between 10 and 25), and
proven to be colonized by P. aeruginosa. Neutropenic
patients and patients treated with immunosuppressive drugs
were not eligible. Patients with ongoing P. aeruginosa
infection, having received macrolides or antibiotics active
against the colonizing P. aeruginosa isolate during the last
14 days were excluded. Patients with proven colonization
by P. aeruginosa were randomized (D-1) and received
either placebo or 300 mg per day iv azithromycin in a
double-blind fashion for a maximum of 20 days (D1 to Dx).
The 300-mg dose was selected taking into account a bio-
availability of 37 % of the usual 500-mg oral dose, the need
for reaching steady state at lung level within 3 days, and
safety considerations.
During the study, the administration of antibiotics
proven to be inactive against the isolated P. aeruginosa
strains was allowed without restrictions. The adminis-
tration of antibiotics with intrinsic activity against
P. aeruginosa strains was only allowed if considered as
mandatory. The prophylaxis study period was restricted to
a maximum of 20 days, and reasons for early discontin-
uation included extubation, death, serious adverse events,
or suspected P. aeruginosa VAP. The diagnosis of
P. aeruginosa VAP was based on the clinical picture,
X-ray scan, a pulmonary infection score (CPIS) C6, as
well as a quantitative culture of a bronchoalveolar lavage
fluid (BAL) yielding [104 CFU/ml P. aeruginosa, in the
absence of other pathogenic bacterial species [17, 18]. An
independent panel of three experts blinded to treatment
confirmed the P. aeruginosa VAP cases.
Clinical sample collection
Starting the first day of proven colonization (D-1), daily
tracheal aspirates (usually 0.3–5 ml) and P. aeruginosa
strains were collected during the entire study period.
Samples were frozen at -80C on site within 15 min, and
sent on dry ice to the reference research laboratory at the
University Hospital Geneva, where all analyses were
performed in a blind fashion.
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Study design and statistical analysis
The study was initiated and financially supported by
Anbics Corporation and a grant from the Swiss Ministry
of Technology (Bundesamt fu¨r Berufsausbildung und
Technologie, Kommission fu¨r Technologie und Innova-
tion, KTI). The study objective as defined per protocol
was to include ten P. aeruginosa VAP cases confirmed by
the independent expert panel. This was based on the
assumption of a 10 % occurrence of pneumonia in
patients colonized by P. aeruginosa in the placebo group,
with a total patient number between 100 and 200
assessable patients. The statistical objective defined in the
study protocol (10 % occurrence of VAP in placebo
group, two-sided, p = 0.10; Fisher’s exact test) required
one P. aeruginosa VAP on azithromycin versus nine on
placebo to reach significance (p = 0.016), or two
P. aeruginosa VAP on azithromycin versus eight on
placebo for a trend (p = 0.092). Because Anbics Corpo-
ration was dissolved prematurely, patient recruitment had
to be stopped before reaching ten confirmed VAP cases.
The investigators continued the laboratory and statistical
analysis of all clinical samples, supported by grants from
the Swiss National Science Foundation. The analysis was
performed on the per-protocol basis. Using the placebo
group of the present trial, we have described patients
persistently colonized with P. aeruginosa strains pro-
ducing elevated levels of the QS-dependent virulence
factor rhamnolipids as a particular risk group to develop
QS-related VAP [19, 20]. Therefore, we performed a
second analysis in this sub-population. Two-sided Fish-
er’s exact tests were used to test differences between
group rates. Odds ratios and 95 % confidence intervals
were also calculated for all parameters. Two-sided inde-
pendent-sample t tests were used to test differences
between group-specific means, assuming equal variances.
Results
Study group description
Out of 92 randomized patients, seven had to be excluded for
major protocol violations including absence of P. aerugin-
osa colonization at study entry, treatment with macrolides
or agents active against the colonizing P. aeruginosa iso-
lates, and premature death (Fig. 1). Forty-two placebo and
43 azithromycin patients were included in the per-protocol
analysis. The treatment groups were well balanced for race,
age, gender, and severity-of-disease (measured by Apache
II score) (Table 1). The most frequent medical reasons for
requiring mechanical ventilation were surgical complica-
tions, deterioration of underlying diseases (congestive heart
and/or acute respiratory failure) and acute respiratory dis-
tress syndrome, which were all equally distributed in both
study groups. Twenty-three azithromycin and 28 placebo
patients received a systemic antibiotherapy during the
study period (p = 0.270, Table 2). Antibiotics devoid of
activity against P. aeruginosa were administered to 21
azithromycin and 25 placebo patients (p = 0.386). Agents
active against P. aeruginosa (ciprofloxacin, aminoglyco-
sides, piperacillin/tazobactam, ceftazidime, aztreonam or
carbapenems) were administered to seven azithromycin
and eight placebo patients (p = 0.783, Table 2) for non-
respiratory tract infections, which occurred mainly during
the last days of the study. In six of these patients (three in
each group), this treatment was active against the colo-
nizing P. aeruginosa isolates. None of them developed
P. aeruginosa VAP and only one placebo patient belonged
to the high-risk group for developing QS-related VAP (as
defined by persistent colonization with isolates producing
high levels of the QS-dependent virulence factor rhamn-
olipids, see below). The colonizing isolates of the nine other
patients (four azithromycin and five placebo) were found to
be resistant to the antibiotic used. Azithromycin exposure
did not lead to an MIC increase comparing the initial and
last P. aeruginosa isolates (data not shown). As compared
to the placebo group, no increased incidence of infections,
whether due to P. aeruginosa or other bacteria, was
detected at other sites in the azithromycin-treated group.
We observed no significant differences in the distribution of
P. aeruginosa genotypes or virulence determinants (pro-
duction of the QS-dependent virulence factors elastase and
rhamnolipids, presence of the Pseudomonas pathogenicity
islands PAI-1 and PAI-2, and the phospholipase gene
ExoU) between the two study groups (Table 3, for details
see online supplementary data). We have recently shown
that patients can be classified into three risk-categories for
VAP according to the production of rhamnolipids of their
colonizing isolates [20]. Whereas 11 placebo [20] and
seven azithromycin-treated (Supplementary Fig. 1B and
C) patients were persistently colonized by isolates pro-
ducing low levels, 13 placebo and 18 treated patients were
colonized by isolates producing intermediate levels, and
five patients in each study group were persistently colo-
nized by isolates producing high levels of rhamnolipids
(Table 3).
Primary clinical endpoints
In the intention-to-treat analysis, the mean duration of
treatment was 9.5 days for the azithromycin-treated and
10.8 days for the placebo groups (Table 4). Eight azith-
romycin and ten placebo patients were treated for the
entire study period of 20 days (p = 0.604). Reasons for
early discontinuation were similar between the treatment
groups when assessing for serious adverse events, non-
pseudomonal pneumonia, extubation, and death unrelated
to P. aeruginosa VAP (Table 4). Concerning the primary
study end-point on the per-protocol population,
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P. aeruginosa VAP occurred in 2/43 azithromycin-treated
and in 6/42 placebo patients (4.7 %, respectively, 14.3 %,
odds ratio; 3.42, CI 95 %; 0.65–18.00, p = 0.156) during
the prophylaxis study window (Table 5). One patient of
each study group (placebo patient #13116 [20] and treated
patient #13115, supplementary Fig. 1A) colonized by
ExoU-positive isolates developed P. aeruginosa VAP.
Clinical efficacy of azithromycin in patients colonized
by isolates producing the QS-dependent virulence
factor rhamnolipids
It became apparent after study completion that many
patients of both study arms were colonized by either
completely or partially QS-deficient isolates. Therefore,
many patients were at low risk of developing ‘‘QS-
dependent’’ VAP. QS-inhibition by azithromycin was
likely to be ineffective, respectively of less clinical benefit
to these patients, as compared to patients colonized by
fully QS-proficient isolates [19, 20]. We therefore per-
formed a subanalysis including only those patients in
whom the QS inhibition by azithromycin could be
effective. First, we compared the occurrence of VAP in
patients colonized by isolates producing intermediate or
high levels of rhamnolipids (Table 3). In this subgroup,
P. aeruginosa VAP occurred in 5/18 placebo and in 1/23
azithromycin-treated patients (Table 5) (odds ratio 8.46,
CI 95 % 0.89–80.59, p = 0.07). Using the placebo group
of the present study, we have previously shown that
92 randomized patients
Intention-to-treat set
45 patients on placebo
Intention-to-treat set
47 patients on azithromycin
3 were excluded:
- 2 had received 
macrolides
- 1 had received 
antibiotics active
against P. aeruginosa
Microbiological set
29 patients
13 were excluded
because of inadequate
sampling
4 were excluded:
- 1 death on day 2 
- 3 were not colonized 
with P. aeruginosa
Per protocol set
42 patients Per protocol set43 patients
13 were excluded
because of inadequate
sampling
11 were colonized by
rhamnolipid negative
isolates
Rhamnolipid-dependent
risk to develop VAP
• Intermediate-risk 13 patients
• High-risk 5 patients
Rhamnolipid-dependent
risk to develop VAP
• Intermediate-risk 18 patients
• High-risk 5 patients
7 were colonized by 
rhamnolipid negative 
isolates
Microbiological set
30 patients
Fig. 1 Patient enrolment and
follow-up
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patients at highest risk for developing QS-related VAP are
those persistently colonized by isolates producing high
levels of rhamnolipids [15]. Considering only this high-
risk subpopulation, P. aeruginosa VAP occurred in 1/5
azithromycin-treated and in 5/5 placebo patients (20 vs.
100 %, p = 0.047) during the prophylaxis study window
(Table 5). One azithromycin-treated patient developed
acute P. aeruginosa pneumonia outside of the prophylaxis
study window (48 h after his extubation and study drug
discontinuation).
Safety and tolerance
The safety profile was assessed in 92 patients up to 7 days
after completion of the prophylaxis study window. The
adverse event (AE) profile was balanced between the
azithromycin and placebo groups. At least one treatment-
Table 1 Baseline characteristics
Variable Azithromycin Placebo
Patient randomization
Patients in the intention-to-treat
group
47 45
Patients in the per-protocol group 43 42
Patient demographics
Race
Caucasian 45 43
Other 2 2
Age: Mean (years ± SD) 59.3 (16.98) 59.7 (15.18)
Gender
Male 28 28
Female 19 17
Apache II score
Mean (±SD) 14.9 (3.82) 14.3 (3.79)
Underlying diseases
Surgical complications 16 (34 %) 18 (40 %)
Visceral 6 (13) 6 (13 %)
Cardiovascular 5 (11 %) 6 (13 %)
Pulmonary 1 (2 %) 1 (2 %)
Transplantation 0 (0 %) 1 (2 %)
Multiple or thoracic trauma 4 (9 %) 4 (9 %)
Acute respiratory distress syndrome 4 (9 %) 4 (9 %)
Aspiration 0 (0 %) 3 (7 %)
Sepsis 4 (9 %) 1 (2 %)
Deterioration of underlying diseases 17 (36 %) 13 (29 %)
Heart failure 6 2
Respiratory failure 11 11
Other 10 (21 %) 14 (22 %)
Table 2 Administration of antibiotics
Type of therapy Azithromycin Placebo p value
Systemic
antibiotherapy
23 (54 %) 28 (67 %) 0.270
Non anti-pseudomonal
antibiotics
21 (49 %) 25 (60 %) 0.386
Anti-pseudomonal
antibiotics
7 (16 %) 8 (19 %) 0.783
Antibiotics active
against colonizing
P. aeruginosa
isolates
3 (7 %) 3 (7 %) 1.0
Table 3 Virulence determinants of initial colonizing isolates
Variable Azithromycin
(n = 30)
Placebo
(n = 29)
p valuea
Genotypes
Number of clones 22 18 NA
Clone F469 2 7 0.080
PAPI-1 3 2 1.0
PAPI-2 26 25 1.0
ExoU 9/26 11/25 0.573
Initial isolates producing
reduced levels of QS-
dependent virulence factors
24 22 0.761
Longitudinal production of rhamnolipids:
High 5 5 1.0
Intermediate 18 13 0.302
Low 7 11 0.267
NA Not applicable (total number of clones)
a Fisher’s exact test
Table 4 Reasons for discontinuation of treatment among azithro-
mycin-treated and placebo patients
Azithromycin
(n = 47)
Placebo
(n = 45)
p valuea
Mean duration of treatment
(days ± SD)
9.5 (5.97) 10.8 (6.11) NS
Patients treated for 20 days 8 10 0.604
Reason for treatment discontinuation
Extubation 24/39 17/35 0.350
Non-pseudomonal
pneumonia
5/39 9/35 0.235
Serious adverse event 3/39 1/35 0.617
Death 2/39 1/35 1.0
Other 4/39 7/35 0.330
a Fisher’s exact test
Table 5 P. aeruginosa VAP in azithromycin-treated and placebo
patients
P. aeruginosa
VAP
Azithromycin Placebo Odds ratio
(CI 95 %)
p valuea
Per-protocol
set
2/43 6/42 3.42
(0.65; 18.00)
0.156
According to rhamnolipid-dependent risk
High and
intermediate
risk
1/23 5/18 8.46
(0.89; 80.59)
0.070
High risk 1/5 5/5 NA 0.048
NA not applicable
a Fisher’s exact test
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related AE was reported for 11 versus 13 % of patients
and serious treatment-related adverse events occurred in
one azithromycin (bradycardia and bronchospasm) and
two placebo patients (ventricular fibrillation, massive
pneumonic infiltrate). In the intention-to-treat set, nine
azithromycin and six placebo patients died, while in the
per-protocol set, six patients of each treatment group died.
None of these deaths was considered drug-related, and the
majority (9/12) occurred after cessation of treatment
(Table 4). No increased risk for infections and/or emer-
gence of resistance to antibiotics was identified. A single
case of pseudomembranous colitis occurred in an azith-
romycin-treated patient.
Discussion
This multicenter, placebo-controlled trial of 92 intubated
patients colonized by P. aeruginosa is the first pilot trial
investigating the efficacy of an anti-virulence strategy to
prevent a major infection. Such new interventions are
desperately needed in view of the rising concern about
infections caused by multi-resistant bacteria. Unfortu-
nately, the study population was smaller than initially
planned as a result of a premature study stop due to dis-
continuation of financial support. Consequently, the study
was not sufficiently powered to detect statistically sig-
nificant differences in the incidence of VAP in the per-
protocol analysis.
We used the macrolide azithromycin, known to be
neither bactericidal nor bacteriostatic on P. aeruginosa,
but which inhibits QS-dependent virulence [11, 14]. We
applied special care to determine both QS-dependent and
QS-independent virulence determinants of sequential
isolates of both study populations since any differences
could have potentially influenced the efficacy of an anti-
virulence intervention. Both study populations were col-
onized by isolates with similar virulence profiles,
however, to our surprise, many patients were colonized by
QS-deficient isolates. Studies performed on the placebo
group of the present trial have shown that these patients
are at low risk of developing QS-related VAP [19, 20].
Obviously such patients could not be anticipated to ben-
efit from the anti-QS activity of azithromycin, reducing
further the population under survey. Added to the pre-
mature stop of patient recruitment, this might explain the
absence of a more significant advantage in the per-pro-
tocol analysis, although an encouraging difference was
seen (4.7 vs. 14.3 %). Moreover the complex work per-
formed on the tracheal isolates and aspirates from the
placebo group allowed us to dissect the role of QS phe-
notypes after completion of the study. Detailed
discussions concerning the implications of genotypes
and virulence phenotypes, as well as dynamics of
P. aeruginosa populations, have been published else-
where [15, 19–21]. It became apparent that only patients
persistently colonized by isolates producing elevated
levels of the QS-dependent virulence factors rhamnolipids
were actually at high risk of developing VAP [20]. While
we observed a trend (p = 0.07) towards less VAP cases in
the subgroup of azithromycin-treated patients colonized
by isolates producing detectable levels of rhamnolipids, a
protective effect of azithromycin became apparent
(p = 0.048) in those treated patients who were colonized
by high rhamnolipid producers, potentially preventing
four out of five of these high-risk patients from devel-
oping VAP.
Two patients, one in the placebo (#13116) and one in
the azithromycin-treated group (#13115), developed VAP
while colonized by lasR-rhlR double mutants. These
isolates carried the exoU gene encoding a phospholipase,
which is translocated through the type III secretion system
(TTSS) and associated with increased mortality from
pneumonia [22]. However, whether colonization with
exoU isolates is a risk factor for progression from colo-
nization to VAP is unknown, and our results suggest that
this is not the case [20]. It appears that exoU is not
associated with the risk for VAP but with its severity.
Interestingly, the TTSS is negatively controlled by QS
[23, 24]. Therefore, inhibition of QS by azithromycin
should have potentially increased the expression of type
III cytotoxins, and therefore the risk for severe VAP. In
the present study, 11 placebo and nine azithromycin-
treated patients were colonized by strains harboring exoU.
As only one patient of each study group developed VAP
while colonized by exoU-positive isolates, this cannot
have accounted for the increased incidence of VAP in the
placebo group.
We have previously shown that a natural cooperative
selection process during P. aeruginosa colonization led to
progressive replacement of QS-proficient by QS-deficient
isolates (cheater cells) due to increase in frequency of
lasR mutants in the placebo group [19]. Remarkably,
using the patients of the present study, we showed that QS
inhibition by azithromycin reduced this natural selection
towards QS-deficient isolates [15]. As a consequence,
treated patients were more frequently colonized at study
end with QS-competent, highly virulent bacteria [15].
This potentially increased their risk of infection once the
prophylaxis was stopped, as suggested by the occurrence
of P. aeruginosa pneumonia outside of the prophylaxis
study window in one treated patient. It should induce
caution upon use of antivirulence strategies in general,
and special care should be taken in future studies in
covering for the risk of post-ventilation infection by
extending prophylaxis after extubation, at least for a few
days.
Our study has several limitations. (1) The study was
underpowered to detect differences in the per-protocol
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analysis and caution has to be taken when extrapolations
are made from analyses performed on sub-groups defined
after study closure. (2) As we did not measure rhamn-
olipid concentrations in respiratory secretions, we cannot
fully exclude whether part of the beneficial effect of
azithromycin could have been mediated through its
immunomodulatory activities, or through modifications of
the lung-resident microbial flora and not through inhibi-
tion of rhamnolipid production [25, 26]. However, one
would expect that any immunosuppressant activity of
azithromycin would have potentially worsened the pro-
gression to and/or severity of an acute infection such as
P. aeruginosa VAP. This was not observed in our trial.
Moreover, the resident microbial flora is more likely to
protect from P. aeruginosa VAP, and therefore its elim-
ination by azithromycin should have increased the risk of
VAP instead of protecting from it. Furthermore, using the
patients of the present trial, we have previously demon-
strated that QS-gene expression, required for rhamnolipid
production, was reduced in the azithromycin-treated as
compared to the placebo group [15]. These results provide
indirect proof that the prevention of VAP in patients
colonized by QS-proficient isolates most likely resulted
from inhibition of QS-gene expression, and reduction of
rhamnolipid production, by azithromycin. (3) Even if the
administration of antibiotics was strictly controlled during
the entire study, three patients in each group received
antibiotics active against their colonizing isolates. Only
one of these patients was colonized by high-rhamnolipid
producers and received placebo. Therefore, it is unlikely
that this might have influenced the outcome of the sub-
group analysis in favor of the azithromycin group. (4) We
did not investigate whether azithromycin potentially
modifies the antibiotic susceptibly of the gut flora.
However, azithromycin did not select for increased
resistance among P. aeruginosa isolates and did not elicit
an increased incidence of infections with resistant non-
Pseudomonal strains.
In conclusion, this study is the first randomized pla-
cebo-controlled trial evaluating the efficacy of an anti-
virulence intervention for the prevention of a major nos-
ocomial infection. Our results suggest that azithromycin
might not prevent P. aeruginosa VAP in all intubated
colonized patients. However, a subgroup of patients, at
high risk of developing P. aeruginosa VAP as a conse-
quence of their colonization by rhamnolipid-producing
isolates, might benefit from the QS-blocking activity of
azithromycin. These data stress the need for a large phase
IIb clinical trial restricted to patients colonized by QS-
proficient isolates to further establish safety and efficacy
of QS inhibition by azithromycin to prevent P. aerugin-
osa VAP.
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